ARID1A and ovarian carcinoma: Indeed, ARID1A‐mutant ovarian cancer cell lines OVISE and TOV21G have displayed sensitivity to EZH2 inhibition, and in wild‐type ARID1A cells, its knockdown confers EZH2 sensitivity.55, 59